A r
re company.
Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.
Age: 24
Groningen, Netherlands
Living with Fabry
“It has been 15 years since a treatment was approved in the U.S. for people with Fabry disease. We’re excited to have a second option available for some people living with Fabry Disease.”
Jerry Walter
Founder & President
National Fabry Disease Foundation
Age: 54
Saddlebrook, NJ
Living with Pompe
Innov
tion
We are at the forefront of developing therapies to potentially address significant unmet needs for devastating rare and orphan diseases.
News & Announcements
February 6, 2019
Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium™
January 18, 2019
Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium™ 2019
January 7, 2019
Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance
January 3, 2019
Amicus Therapeutics Announces Phase 1/2 Study of Gene Therapy for CLN3 Batten Disease
December 20, 2018
Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
International News
More newsFeatured Topics
A Rare Company - Bold Commitment
Every day at Amicus we strive to fulfill the bold commitment we’ve made to the rare disease community. This commitment keeps us at the forefront of innovation as we work to develop medicines for those who need them most.
A Rare Company – Persistence & Resilience
At Amicus Therapeutics, we believe that we should never give up on our mission to help people with rare diseases. This video in our #RareCompany series talks about the importance of persistence & resilience in our daily work of developing medicines and serving the rare disease community.
A Rare Company – Extraordinary Patient Focus
At Amicus, patient-centricity is in our DNA. See how our commitment to patients goes further than just our medicines and expands out to the rare disease community at large.